Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Waters logoWaters WAT

Waters said it entered into definitive agreements on July 13, 2025 for a Reverse Morris Trust deal involving Becton, Dickinson and Company's (BD) Biosciences and Diagnostic Solutions business.

8-KEntry into a Material Definitive AgreementFiled Period of report Summary published (UTC)

Key points

AI summary
  1. Waters said it entered into definitive agreements on July 13, 2025 for a Reverse Morris Trust deal involving Becton, Dickinson and Company's (BD) Biosciences and Diagnostic Solutions business.

  2. The company said that, upon completion of the merger, existing Waters shareholders will own approximately 60.8% and former SpinCo shareholders will own approximately 39.2% of the fully diluted shares. It said the exchange ratio could be adjusted upward so that former SpinCo shareholders own at least 50.5%, as required for the tax-free treatment.

  3. The company said that before the distribution, SpinCo will make a cash payment of $4.0 billion to BD, which is subject to adjustment. It also said it entered into a 364-day bridge loan commitment letter with a financial institution for $1.8 billion, which it said is intended to fund part of any Waters Special Dividend and transaction-related fees and expenses.

  4. Waters cited shareholder approval of the share issuance, receipt of a private letter ruling from the Internal Revenue Service, and U.S. and international regulatory approvals as conditions to closing the merger. It said either party may terminate if the merger is not completed by July 13, 2026, and that under certain circumstances Waters must pay BD a termination fee of $733 million.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Waters Enters Reverse Morris Trust Deal for BD Biosciences Business

Waters said it entered into definitive agreements on July 13, 2025 for a Reverse Morris Trust deal involving Becton, Dickinson and Company's (BD) Biosciences and Diagnostic Solutions business.

Source · Based on the filing body and exhibits

Post-Merger Ownership Split: 60.8% vs. 39.2%

The company said that, upon completion of the merger, existing Waters shareholders will own approximately 60.8% and former SpinCo shareholders will own approximately 39.2% of the fully diluted shares. It said the exchange ratio could be adjusted upward so that former SpinCo shareholders own at least 50.5%, as required for the tax-free treatment.

Source · Based on the filing body and exhibits

SpinCo's $4.0 billion Cash Payment to BD and Bridge Loan

The company said that before the distribution, SpinCo will make a cash payment of $4.0 billion to BD, which is subject to adjustment. It also said it entered into a 364-day bridge loan commitment letter with a financial institution for $1.8 billion, which it said is intended to fund part of any Waters Special Dividend and transaction-related fees and expenses.

Source · Based on the filing body and exhibits

Closing Conditions and $733 million Termination Fee

Waters cited shareholder approval of the share issuance, receipt of a private letter ruling from the Internal Revenue Service, and U.S. and international regulatory approvals as conditions to closing the merger. It said either party may terminate if the merger is not completed by July 13, 2026, and that under certain circumstances Waters must pay BD a termination fee of $733 million.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.